Vivimed Labs Limited has announced that it has received approval from the Government of India (Director General of Health Services) to manufacture and market Favipiravir Tablet 200 mg and 400 mg under the brand name Vivimed “Favulous” across India.
Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd, said: “With the huge spike in Covid19 cases reported daily in India, there is an urgent need to provide more treatment options for healthcare professionals. We are launching ‘Favulous’ at a competitive price to make the drug accessible to more and more patients, thus ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at the forefront of India’s fight against Covid-19. “
Favipiravir is used for the treatment of mild to moderate cases of Covid-19. Favipiravir is one of the leading oral antiviral treatments approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.
Favipiravir recorded the highest sales in April 2021. To register as a leading pharmaceutical brand in the domestic market (Fabiflu: Glenmark: 762 Crores).
The company will work closely with various governments and the medical community to ensure the availability of “Favulous” to patients across the country.
On Sensex, Vivimed closed on the upper circuit of Rs28.45 per coin up 4.98%.